Illumina, Inc. $ILMN Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. cut its position in Illumina, Inc. (NASDAQ:ILMN) by 3.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,686,692 shares of the life sciences company’s stock after selling 54,461 shares during the quarter. Baillie Gifford & Co.’s holdings in Illumina were worth $160,185,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. WCM Investment Management LLC increased its position in shares of Illumina by 5.9% during the 2nd quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after purchasing an additional 247,460 shares during the period. Loomis Sayles & Co. L P grew its stake in Illumina by 1.9% during the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock valued at $403,158,000 after acquiring an additional 78,317 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Illumina by 55.3% in the second quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after acquiring an additional 1,174,295 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Illumina by 0.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock worth $272,921,000 after purchasing an additional 21,342 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Illumina by 1.9% in the second quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after acquiring an additional 35,167 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Buying and Selling

In other Illumina news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. The trade was a 1.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Scott Gottlieb purchased 500 shares of the stock in a transaction dated Monday, November 3rd. The stock was purchased at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the acquisition, the director owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This represents a 4.16% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 2.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ILMN shares. JPMorgan Chase & Co. raised their price objective on shares of Illumina from $105.00 to $130.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Stifel Nicolaus upped their price target on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday. Canaccord Genuity Group lifted their target price on Illumina from $112.00 to $130.00 and gave the company a “hold” rating in a research report on Monday, December 22nd. UBS Group upped their price target on shares of Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Finally, Evercore ISI reaffirmed an “outperform” rating and issued a $155.00 price objective on shares of Illumina in a research report on Monday, January 5th. Six equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $124.47.

Illumina Stock Performance

NASDAQ:ILMN opened at $150.28 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.53. The stock’s 50-day moving average is $135.20 and its 200-day moving average is $113.14. The stock has a market cap of $22.96 billion, a P/E ratio of 33.70, a price-to-earnings-growth ratio of 2.56 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the business earned $1.14 earnings per share. Illumina’s revenue for the quarter was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.